Thermo Fisher Scientific (TMO) has had a varied performance over the past year, with some stock weaknesses being reported while ultimately remaining a favourite among large-cap value stocks. Recent fluctuations include the sale of parts of the Diagnostic Division and a cut in profit forecasts for 2025, largely due to tariff hits and research funding cuts.
However, prolonged overselling and various positive factors make TMO an attractive buy for investors. These include their decision to unveil next-generation Mass Spectrometers, the launch of the 5L DynaDrive Single-Use Bioreactor and their exploration of a $4 billion Diagnostics Sale, which reinforces their position as a key player in the field.
New investments to support customer manufacturing indicate a robust business model and comprehensive SWOT analysis. Future prospects for financial performance remain strong, with Thermo Fisher beating Q1 2025 earnings expectations and benefiting from extensive collaboration for advanced biological understanding, suggesting promising growth and performance in the coming years.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Fri, 20 Jun 2025 12:00:24 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor -4
